Acute coronary syndromes

Use of OCT in Calcified Lesions: Results from a Subanalysis of ILUMIEN IV

Coronary calcification represents one of the main challenges in percutaneous coronary intervention (PCI), as it is associated...

Dr. Omar Tupayachi - 23 September, 2025

Acute coronary syndromes

Flow Protocols in VA-ECMO: Impact on PCWP in Cardiogenic Shock

The use of peripheral femoro-femoral venoarterial (VA) extracorporeal membrane oxygenation (ECMO) has globally consolidated and is the...

Dr. Omar Tupayachi - 15 September, 2025

Acute coronary syndromes

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

The routine use of beta-blockers after acute myocardial infarction (AMI) has been a historical recommendation based on...

Dr. Omar Tupayachi - 4 September, 2025

Acute coronary syndromes

ESC 2025 | What Should We Do With Beta-Blockers Post-MI in Patients With Preserved LVEF?

The evidence supporting the use of beta-blockers after myocardial infarction (MI) is strong in patients with ventricular...

Dr. Juan Manuel Pérez - 3 September, 2025

Acute coronary syndromes

ESC 2025 | DUAL-ACS: Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes

The DUAL-ACS trial, a randomized multicenter study, was designed to evaluate whether a strategy of P2Y12 inhibitor...

Dr. Juan Manuel Pérez - 3 September, 2025

Acute coronary syndromes

ESC 2025 | OPTION-STEMI: Timing of Complete Revascularization During the Initial Hospitalization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease

In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD), the optimal timing...

Dr. Juan Manuel Pérez - 3 September, 2025

Acute coronary syndromes

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) remains subject to controversy....

Dr. Omar Tupayachi - 3 August, 2025

Acute coronary syndromes

Use of Plaque Modifying Devices in Calcified Left Main Lesions

Treating severely calcified left main coronary artery (LMCA) lesions is one of the greatest challenges in interventional...

Dr. Omar Tupayachi - 25 July, 2025

Acute coronary syndromes

Use of OCT in Calcified Lesions: Results from a Subanalysis of ILUMIEN IV

Flow Protocols in VA-ECMO: Impact on PCWP in Cardiogenic Shock

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

ESC 2025 | What Should We Do With Beta-Blockers Post-MI in Patients With Preserved LVEF?

ESC 2025 | DUAL-ACS: Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes

ESC 2025 | OPTION-STEMI: Timing of Complete Revascularization During the Initial Hospitalization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

Use of Plaque Modifying Devices in Calcified Left Main Lesions

Últimas Noticias

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Noticias Institucionales

SOLACI Wishes You Happy Holidays

Condolences on the passing of Cristiam Arancibia

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Accesos